Charles River Labs Intl Stock
Price
Target price
€177.85
€177.85
-0.500%
-0.9
-0.500%
€247.61
09:30 / Tradegate
WKN: 939391 / Symbol: CRL / Name: Charles River Lb / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Charles River Labs Intl Stock
Charles River Labs Intl shows a slight decrease today, losing -€0.900 (-0.500%) compared to yesterday.
Charles River Labs Intl is currently one of the favorites of our community with 13 Buy predictions and no Sell predictions.
With a target price of 247 € there is a positive potential of 38.88% for Charles River Labs Intl compared to the current price of 177.85 €.
Pros and Cons of Charles River Labs Intl in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Charles River Labs Intl vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Charles River Labs Intl | -0.500% | -2.589% | -16.589% | -8.121% | -16.080% | -52.961% | - |
| Ironwood Pharmaceuticals | -1.320% | 1.339% | -23.697% | -45.629% | -55.490% | -58.727% | -45.550% |
| Arrowhead Pharmaceuticals Inc. | -8.710% | 8.804% | 0.375% | -5.453% | -14.418% | -58.563% | -25.502% |
| Iovance Biotherapeutics Inc. | -0.710% | -1.312% | 47.603% | 84.607% | 34.862% | -48.958% | -44.579% |
Comments
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target lowered by analysts at UBS Group AG from $290.00 to $240.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target lowered by analysts at Evercore ISI from $265.00 to $225.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target lowered by analysts at Robert W. Baird from $271.00 to $239.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
News
Charles River Laboratories Announces Second-Quarter 2024 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2024. For the quarter, revenue was $1.03 billion, a decrease of 3.2% from $1.06
Charles River Collaborates with Patient Advocacy Group, FOXG1 Research Foundation to Advance Rare Disease Gene Therapy Development
Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model to independently
Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
Charles River Laboratories International, Inc. (NYSE: CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that